Haematopoietic stem cell transplantation: Current concepts and novel therapeutic strategies

British Medical Bulletin

Volumn 93, Issue 1, 2010, Pages 85-103

  Leung, Anskar Y H ^a   Kwong, Yok Lam ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Graft versus host disease; Haematopoietic stem cell transplantation; Mobilization; Reduced intensity conditioning; Umbilical cord blood

Indexed keywords

ALEMTUZUMAB; BECLOMETASONE; BUSULFAN; CD34 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; ERYTHROPOIETIN; EVEROLIMUS; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; IDARUBICIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PARATHYROID HORMONE; PLERIXAFOR; RAPAMYCIN; RECOMBINANT STEM CELL FACTOR; RITUXIMAB; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN PRESENTING CELL; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CELL ACTIVATION; CHEMOPROPHYLAXIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTAPHERESIS; DONOR LYMPHOCYTE INFUSION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; ENGRAFTMENT; FANCONI ANEMIA; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOINCOMPATIBILITY; HODGKIN DISEASE; HOSPITALIZED CHILD; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NEPHROTOXICITY; NEUTROPHIL COUNT; NONHUMAN; ORGAN DONOR; PERIPHERAL BLOOD STEM CELL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; STEM CELL MOBILIZATION; T LYMPHOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TISSUE INJURY; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING;

EID: 77949387143     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldp040     Document Type: Review

References (40)

1. Thomas ED (1999) A history of haemopoietic cell transplantation. Br J Haematol, 105, 330-339.
2. Bensinger W, DiPersio JF, McCarty JM (2009) Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant, 43, 181-195.
3. Levesque JP, Winkler IG (2008) Mobilization of hematopoietic stem cells: state of the art. Curr Opin Organ Transplant, 13, 53-58.
4. Brown JA, Boussiotis VA (2008) Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol, 127, 286-297.
5. Antin JH (2007) Reduced-intensity stem cell transplantation. Hematology Am Soc Hematol Educ Program, 47-54.
6. Sandmaier BM, Mackinnon S, Childs RW (2007) Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant, 13 (Suppl. 11), 87-97.
7. Pollack SM, O'connor TP Jr, Hashash J, Tabbara IA (2009) Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review. Am J Clin Oncol [Epub ahead of print].
8. Ferrara J, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet, 373, 1550-1561.
9. Styczynski J, Gil L, EBMT Paediatric Diseases Working Party (2008) Prevention of infectious complications in pediatric HSCT. Bone Marrow Transplant, 42 (Suppl. 2), S77-S81.
10. Stotler C, Bolwell B, Sobecks R et al. (2009) Are backup BM harvests worthwhile in unrelated donor allogeneic transplants? Bone Marrow Transplant [Epub ahead of print].
11. Shaw BE, Russell NH (2008) Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant, 41, 495-503.
12. Ketterer N, Salles G, RabaMet al. (1998) High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood, 91, 3148-3155.
13. To LB, Juttner CA (1987) Peripheral blood stem cell autografting: a new therapeutic option for AML? Br J Haematol, 66, 285-288.
14. Russell N, Mesters R, Schubert J et al. (2008) A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica, 93, 405-412.
15. Harousseau JL, Moreau P (2009) Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med, 360, 2645-2654.
16. Pusic I, Jiang SY, Landua S et al. (2008) Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant, 14, 1045-1056.
17. Flomenberg N, Devine SM, Dipersio JF et al. (2005) The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood, 106, 1867-1874.
18. Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G (2009) Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant, 15, 249-256.
19. Fruehauf S, Seeger T, Maier P et al. (2006) The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol, 34, 1052-1059.
20. Zohren F, Toutzaris D, Klärner V, Hartung HP, Kieseier B, Haas R (2008) The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood, 111, 3893-3895.
21. Ballen KK, Shpall EJ, Avigan A et al. (2007) Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant, 13, 838-843.
22. Gluckman E, Broxmeyer HA, Auerbach AD et al. (1989) Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med, 321, 1174-1178.
23. Kurtzberg J, Prasad VK, Carter SL et al. (2008) Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood, 112, 4318-4327.
24. Wagner JE, Barker JN, DeFor TE et al. (2002) Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood, 100, 1611-1618.
25. Rocha V, Labopin M, Sanz G et al. (2004) Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med, 351, 2276-2285.
26. Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE (2001) Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood, 97, 2957-2961.
27. Laughlin MJ, Eapen M, Rubinstein P et al. (2004) Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med, 351, 2265-2275.
28. Barker JN, Weisdorf DJ, DeFor TE et al. (2005) Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood, 105, 1343-1347.
29. Brunstein CG, Barker JN, Weisdorf DJ et al. (2007) Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood, 110, 3064-3070.
30. Ram R, Grafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O (2009) Prophylaxis regimens for GVHD; systematic review and meta-analysis. Bone Marrow Transplant, 43, 643-653.
31. Platzbecker U, von Bonin M, Goekkurt E et al. (2009) Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstructive syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant, 15, 101-108.
32. Cutler C, Stevenson K, Kim HT et al. (2008) Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood, 112, 4425-4431.
33. Bacigalupo A (2005) Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant, 35, 225-231.
34. Wagner JE, Thompson JS, Carter SL, Kernan NA, Unrelated Donor Marrow Transplantation Trial (2005) Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet, 366, 733-741.
35. Ho VT, Culter C (2008) Current and novel therapies in acute GVHD. Best Pract Res Clin Haematol, 21, 223-237.
36. Hockenbery DM, Cruickshank S, Rodell TC et al. (2007) A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisolone-sparing therapy for gastrointestinal graft-versus-host disease. Blood, 109, 4557-4563.
37. Deans RJ, Moseley AB (2000) Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol, 28, 875-884.
38. Le Blanc K, Rasmusson I, Sundberg B et al. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363, 1439-1441.
39. Lazarus HM, Koc ON, Devine SM et al. (2005) Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant, 11, 389-398.
40. Le Blanc K, Frassoni F, Ball L et al. (2008) Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371, 1579-1586.